COECSA, Journal, Ophthalmology
Ocular surface disease among glaucoma patients in Ibadan, South-West Nigeria
Download PDF Article


Benzalkonium chloride,
Ocular surface disease

How to Cite

Sarimiye TF, Fasina O, Ashaye A, Bekibele C, Olawoye O. (2023). Ocular surface disease among glaucoma patients in Ibadan, South-West Nigeria. The Journal of Ophthalmology of Eastern, Central and Southern Africa, 15(01). Retrieved from


Objective: To study the frequency and severity of ocular surface disease among glaucoma patients attending
the Eye Clinic of the University College Hospital, Ibadan, Nigeria.

Methods: A hospital-based, cross sectional study was carried out at the Eye Clinic of the University College
Hospital, Ibadan. After a detailed ocular examination, each respondent completed an Ocular Surface Disease
Index (OSDI) questionnaire and performed central visual field assessment. Participants were analyzed for the
effect of anti-glaucoma topical medications (all BAK-preserved) and glaucoma severity on ocular surface disease.

Results: A total of 122 consecutive glaucoma patients were studied. Males accounted for 45.1%. Increasing daily
drops of anti-glaucoma medication was significantly associated with increasing side effects such as redness,
stinging and peppery sensations (p < 0.01). Eighty four patients representing 68.9% had some form of OSD using
the OSDI score. The OSDI scores and the number of patients with OSD significantly increased with increasing
glaucoma severity (p < 0.01).

Conclusion: Ocular surface disease was found to be associated with glaucoma severity and use of BAK-preserved
topical anti-glaucoma medications.
Key words: Benzalkonium chloride, Glaucoma, Ibadan, Ocular surface disease

Download PDF Article


The definition and classification of dry eye

disease: report of the Definition and Classification

Subcommittee of the International Dry Eye

Workshop. Ocul Surf. 2007; 5(2):75–92.

Pflugfelder SC. Prevalence, burden and

pharmacoeconomics of dry eye disease. Am J Manag

Care. 2008; 14(3 Suppl):S102-S106.

Smith JA. The epidemiology of dry eye disease:

report of the Epidemiology Subcommittee of the

International Dry Eye WorkShop. Ocul Surf. 2007;


Brewitt H, Sistani F. Dry eye disease: the scale of

the problem. Surv Ophthalmol. 2001; 45(Suppl 2):


Mathers WD, Choi D. Cluster analysis of patients

with ocular surface disease, Blepharirtis and dry eye.

Arch Ophthalmol. 2004; 122(1):1700-1704.

Leung EW, Medeiros FA, Weinreb RN. Prevalence

of ocular surface disease in glaucoma patients.

J Glaucoma. 2008; 17(5): 350-355.

Quigley H, Browman AT. The number of people

with glaucoma worldwide in 2010 and 2020. Br J

Ophthalmol. 2006; 90(3): 267-267.

Friedman DS, Wolfs RC, O’Colmain BJ, Klein BE,

Taylor HR, West S, et al. Prevalence of open-angle

glaucoma among adults in the United States. Arch

Ophthalmol. 2004; 122(4): 532-538.

Klaver CC, Wolfs RC, Vingering JR, Hofman A,

de Jong PT. Age-specific prevalence and causes

of blindness and visual impairment in an older

population: the Rotterdam Study. Arch Ophthalmol.

; 116:653-658.

Pizzarello LD. The dimensions of the problems of

eye disease among the elderly. Ophthalmology.

; 94:1191-1195.

Stewart WC, Stewart JA, Nelson LA. Ocular surface

disease in patients with ocular hypertension and

glaucoma. Curr Eye Res. 2011; 35(5):391-398.

Wilson WS, Duncan AJ, Jay JL. Effect of

benzalkonium chloride on the stability of the

precorneal tear film in rabbit and man. Br J

Ophthalmol. 1975; 59:667-669

Baudouin C, de Lunardo C. Short-term comparative

study of topical 2% carteolol with and without

benzalkonium chloride in healthy volunteers. Br J

Ophthalmol. 1998; 82:39-42.

Yee RW. The effect of drop vehicle on the efficacy

and side effects of topical glaucoma therapy: a

review. Curr Opin Ophthal. 2007; 18: 134-139.

Herreras JM, Pastor JC, Calonge M. Ocular

surface alteration after long term treatment with

an antiglaucomatous drug. Ophthalmology. 1992;


Baudouin C, Labbe A, Liang H, Pauly A, Brignole-

Baudouin F. Preservatives in eyedrops: the good,

the bad and the ugly. Prog Retin Eye Res. 2010;


Skalicky SE, Goldberg I, McCluskey P. Ocular

surface disease and quality of life in patients with

glaucoma. Am J Ophthalmol. 2012; 135(1):1–9.

Schiffman RM, Christianson MD, Jacobsen G,

Hirsch JD, Reis BL. Reliability and validity of the

ocular Surface Disease Index. Arch Ophthalmol.

; 118(5):615-621.

Garcia-Feijo J, Sampaolesi JR. A multicenter

evaluation of ocular surface disease prevalence in

patients with glaucoma. C. Ophthalmol. 2012; 6:


Barisic F, Krolo I, Popovic-Suic S, Sesar I, Simic-

Prskalo M, et al. Prevalence of Ocular Surface

Disease in Patients with Glaucoma using Topical

Antiglaucoma Medications. J Clin Exp Ophthalmol.

; 5:334. doi: 10.4172/2155-9570.1000334.

Katz G, Springs CL, Craven ER, Montecchi-Palmer

M. Ocular surface disease in patients with glaucoma

or ocular hypertension treated with either BAKpreserved

latanoprost or BAK-free travoprost. Clin

Ophthalmol. 2010; 4:1253-1261.


Download data is not yet available.